Clinical pharmacokinetics of second generation antisense oligonucleotides

Expert Opinion on Drug Metabolism and Toxicology

Volumn 9, Issue 2, 2013, Pages 169-182

  Yu, Rosie Z ^a   Grundy, John S ^a   Geary, Richard S ^a  

^a ISIS PHARMACEUTICALS   (United States)

Author keywords

Bioanalytical methods; Clinical; Drug drug interaction; Human; Pharmacokinetics; Plasma protein binding; Second generation antisense oligonucleotide; Urinary excretion

Indexed keywords

AEG 35156; ANTISENSE OLIGONUCLEOTIDE; APOLIPOPROTEIN B100; ATORVASTATIN; CLUSTERIN; CUSTIRSEN; DNA METHYLTRANSFERASE 1; GATAPARSEN; HEAT SHOCK PROTEIN 27; ISIS 104838; ISIS 113715; LY 2275796; MG 98; MIPOMERSEN; OGX 427; PROTEIN TYROSINE PHOSPHATASE 1B; RNA; SIMVASTATIN; SURVIVIN; UNCLASSIFIED DRUG; X LINKED INHIBITOR OF APOPTOSIS;

AREA UNDER THE CURVE; DATA BASE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SOLUBILITY; HUMAN; HYPERCHOLESTEROLEMIA; INFLAMMATORY DISEASE; KIDNEY CARCINOMA; MAXIMUM PLASMA CONCENTRATION; NEOPLASM; NON INSULIN DEPENDENT DIABETES MELLITUS; PHARMACOKINETICS; REVIEW; TIME TO MAXIMUM PLASMA CONCENTRATION;

ANIMALS; DRUG INTERACTIONS; HUMANS; OLIGONUCLEOTIDES, ANTISENSE; PHARMACEUTICAL PREPARATIONS; PROTEIN BINDING;

EID: 84872432062     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1517/17425255.2013.737320     Document Type: Review

References (69)

1. Wagner RW. Gene inhibition using antisense oligodeoxynucleotides. Nature 1994;372(6504):333-5 (Pubitemid 24363432)
2. Altmann K-H, Dean NM, Fabbro D, et al. Second generation of antisense oligonucleotides: from nuclease resistance to biological efficacy in animals. Chimia (Aarau) 1996;50(4):168-76 (Pubitemid 126059715)
3. Lima WF, Venkatraman M, Crooke ST. The influence of antisense oligonucleotide-induced RNA structure on E. coli RNase H1 activity. J Biol Chem 1997;272(29):18191-9 (Pubitemid 27306406)
4. Manoharan M. 2¢-carbohydrate modifications in antisense oligonucleotide therapy: importance of conformation, configuration and conjugation. Biochim Biophys Acta 1999;1489(1):117-30
5. McKay RA, Miraglia LJ, Cummins LL, et al. Characterization of a potent and specific class of antisense oligonucleotide inhibitor of human protein kinase C-a expression. J Biol Chem 1999;274:1715-22
6. Henry SP, Geary RS, Yu R, Levin AA. Drug properties of second-generation antisense oligonucleotides: how do they measure up to their predecessors? Current Opinion in Investigational Drugs 2001;2(10):1444-9 (Pubitemid 32994399)
7. Bennett CF, Swayze EE. RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform. Annu Rev Pharmacol Toxicol 2010;50:259-93
8. Chi KN, Eisenhauer E, Fazli L, et al. A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2¢-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer. J Natl Cancer Inst 2005;97(17):1287-96 (Pubitemid 41535369)
9. Jones BA, Schreiber AD. mRNA as a therapeutic target in lung disease. Drug Design Reviews 2005;2(5):361-72 (Pubitemid 41195661)
10. Kjems L. New targets for glycemic control protein-tyrosine-phosphatase-1b antisense inhibitor. The American Diabetes Association's 65th Annual Meeting; 10 - 14 June 2005; San Diego, California; 2005
11. Sewell LK, Geary RS, Baker BF, et al. Phase I trial of ISIS 104838, a 2¢-methoxyethyl modified antisense oligonucleotide targeting tumor necrosis factor-alpha. J Pharmacol Exp Ther 2002;303(3):1334-43 (Pubitemid 35424421)
12. Wei N, Fiechtner J, Boyle D, et al. Synovial Biomarker Study of ISIS 104838, An Antisense Oligodeoxynucleotide Targeting TNF-alpha, in Rheumatoid Arthritis. 67th Annual Meeting of the American College of Rheumatology (ACR); 23 -28 October 2003; Orlando, Florida; 2003
13. Chi KN, Siu LL, Hirte H, et al. A phase I study of OGX-011, a 2¢-methoxyethyl phosphorothioate antisense to clusterin, in combination with docetaxel in patients with advanced cancer. Clin Cancer Res 2008;14(3):833-9 (Pubitemid 351231167)
14. Winquist E, Knox J, Ayoub JP, et al. Phase II trial of DNA methyltransferase 1 inhibition with the antisense oligonucleotide MG98 in patients with metastatic renal carcinoma: A National Cancer Institute of Canada Clinical Trials Group investigational new drug study. Invest New Drugs 2006;24(2):159-67 (Pubitemid 43723908)
15. Athyros VG, Kakafika AI, Tziomalos K, et al. Antisense technology for the prevention or the treatment of cardiovascular disease: the next blockbuster? Expert Opin Investig Drugs 2008;17(7):969-72
16. Kastelein J, Trip M, Davidson MH. Safety and activity of Isis 301012 in heterozygous familial hypercholesterolemia. J Clin Lipidol 2007;1:475
17. Kastelein JJ, Wedel MK, Baker BF, et al. Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B. Circulation 2006;114(16):1729-35 (Pubitemid 44607121)
18. Yoshitaka I, Enyu I, Shiro T, Hiromi R. Oligonucleotiditic therapeutics. Expert Opin Drug Discov 2008;3(9):991-6
19. Tilley JW. Very late antigen-4 integrin antagonists. Expert Opinion Therapeutic Patents 2008;18:841-59
20. Jain KK. Drug delivery in central nervous system disorders: technologies, companies and markets. Jain PharmaBiotech; Basel, Switzerland: 2012
21. Fattal E, Bochot A. Antisense oligonucleotides, aptamers and SiRNA: promises for the treatment of ocular diseases. Arch Soc Esp Oftalmol 2006;81(1):3-4; 5-6
22. Oh CK, Geba GP, Molfino N. Investigational therapeutics targeting the IL-4/IL-13/STAT-6 pathway for the treatment of asthma. Eur Respir Rev 2010;19(115):46-54
23. Dean N. An antisense oligonucleotide (EXC 001) targeting connective tissue growth factor as a novel approach to reduce skin scarring. TIDES Oligonucleotide and Peptide Research, Technology and Product Development; 20 - 23 May 2012; Las Vegas, NV; 2012
24. Raal FJ, Santos RD, Blom DJ, et al. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet 2010;375(9719):998-1006
25. Visser ME, Witztum JL, Stroes ES, Kastelein JJ. Antisense oligonucleotides for the treatment of dyslipidaemia. Eur Heart J 2012;33(12):1451-8
26. Amidon GL, Lennernas H, Shah VP, Crison Jr. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 1995;12(3):413-20
27. Hardee GE, Tillman LG, Geary RS. Routes and formulations for delivery of antisense oligonucleotides. In: Crooke ST, editor. Antisense drug technology, principles, strategies and applications. Taylor & Francis Group; Boca Raton, FL: 2007. p. 217-236
28. Geary RS, Wancewicz E, Matson J, et al. Effect of dose and plasma concentration on liver uptake and pharmacologic activity of a 2¢-methoxyethyl modified chimeric antisense oligonucleotide targeting PTEN. Biochem Pharmacol 2009;78(3):284-91
29. Koller E, Vincent TM, Chappell A, et al. Mechanisms of single-stranded phosphorothioate modified antisense oligonucleotide accumulation in hepatocytes. Nucleic Acids Res 2011;39(11):4795-807
30. Stewart DJ, Donehower RC, Eisenhauer EA, et al. A phase I pharmacokinetic and pharmacodynamic study of the DNA methyltransferase 1 inhibitor MG98 administered twice weekly. Ann Oncol 2003;14(5):766-74 (Pubitemid 36621778)
31. Schimmer AD, Estey EH, Borthakur G, et al. Phase I/II trial of AEG35156 X-linked inhibitor of apoptosis protein antisense oligonucleotide combined with idarubicin and cytarabine in patients with relapsed or primary refractory acute myeloid leukemia. J Clin Oncol 2009;27(28):4741-6
32. Yu RZ, Kim T-W, Hong A, et al. Cross-Species Pharmacokinetic Comparison from Mouse to Man of a Second Generation Antisense Oligonucleotide ISIS 301012, Targeting Human ApoB-100. Drug Metab Dispos 2007;35:460-8 (Pubitemid 46333910)
33. Hong DS, Kurzrock R, Oh Y, et al. A phase 1 dose escalation, pharmacokinetic, and pharmacodynamic evaluation of eIF-4E antisense oligonucleotide LY2275796 in patients with advanced cancer. Clin Cancer Res 2011;17(20):6582-91
34. Tanioka M, Nokihara H, Yamamoto N, et al. Phase I study of LY2181308, an antisense oligonucleotide against survivin, in patients with advanced solid tumors. Cancer Chemother Pharmacol 2011;68(2):505-11
35. Geary RS, Matson J, Levin AA. A nonradioisotope biomedical assay for intact oligonucleotide and its chain-shortened metabolites used for determination of exposure and elimination half-life of antisense drugs in tissue. Anal Biochem 1999;274(2):241-8 (Pubitemid 29489495)
36. Yu RZ, Geary RS, Leeds JM, et al. Comparison of pharmacokinetics and tissue disposition of an antisense phosphorothioate oligonucleotide targeting human Ha-ras mRNA in mouse and monkey. J Pharm Sci 2001;90(2):182-93
37. Bigelow JC, Chirin LR, Mathews LA, McCormack JJ. High-performance liquid chromatographic analysis of phosphorothioate analogues of oligodeoxynucleotides in biological fluids. J Chromatogr 1990;533:133-40
38. Chen S-H, Qian M, Brennan JM, Gallo JM. Determination of antisense phoshorothioate oligonucleotides and catabolites in biological fluids and tissue extracts using anion-exchange highperformance liquid chromatography and capillary gel electrophoresis. J Chromatogr 1997;692:43-51 (Pubitemid 27208465)
39. Geary RS, Ushiro-Watanabe T, Truong L, et al. Pharmacokinetic properties of 2¢-O-(2-methoxyethyl)-modified oligonucleotide analogs in rats. J Pharmacol Exp Ther 2001;296(3):890-7 (Pubitemid 32187362)
40. Leeds JM, Graham MJ, Troung L, Cummins LL. Quantitation of phosphorothioate oligonucleotides in human plasma. Anal Biochem 1996;235:36-43 (Pubitemid 26065194)
41. Yu RZ, Geary RS, Levin AA. Application of novel quantitative bioanalytical methods for pharmacokinetic and pharmacokinetic/pharmacodynamic assesments of antisense oligonucleoutides. Curr Opin Drug Discov Devel 2004;7(2):195-203 (Pubitemid 44111951)
42. Geary RS. Antisense oligonucleotide pharmacokinetics and metabolism. Expert Opin Drug Metab Toxicol 2009;5(4):381-91
43. Yu RZ, Lemonidis KM, Graham MJ, et al. Cross-species comparison of in vivo PK/PD relationships for second-generation antisense oligonucleotides targeting apolipoprotein B-100. Biochem Pharmacol 2009;77(5):910-19
44. Legakis H, Carriero S. Bioanalysis of therapeutic oligonucleotides using hybridization-based immunoassay techniques. In: Bonilla JV, Srivatsa S, editors. Handbook of analysis of oligonucleotides and related products. Taylor & Francis Group, Boca Raton, FL; 2011. p. 265-283
45. Geary RS, Bradley JD, Watanabe T, et al. Lack of pharmacokinetic interaction for ISIS 113715, a 2¢-0. methoxyethyl modified antisense oligonucleotide targeting protein tyrosine phosphatase 1B messenger RNA, with oral antidiabetic compounds metformin, glipizide or rosiglitazone. Clin Pharmacokinet 2006;45(8):789-801 (Pubitemid 44182276)
46. Akdim F, Visser ME, Tribble DL, et al. Effect of mipomersen, an apolipoprotein B synthesis inhibitor, on low-density lipoprotein cholesterol in patients with familial hypercholesterolemia. Am J Cardiol 2010;105(10):1413-19
47. Nokihara H, Yamamoto N, Yamada Y, et al. A phase 1 study of an antisense oligonucleotide against survivin (LY2181308) in Japanese patients with solid tumors. Mol Cancer Ther 2009;8(Suppl 12):B48
48. Talbot DC, Ranson M, Davies J, et al. Tumor survivin is downregulated by the antisense oligonucleotide LY2181308: a proof-of-concept, first-in-human dose study. Clin Cancer Res 2010;16(24):6150-8
49. Akdim F, Tribble DL, Flaim JD, et al. Efficacy of apolipoprotein B synthesis inhibition in subjects with mild-to-moderate hyperlipidaemia. Eur Heart J 2011;32(21):2650-9
50. Dean E, Jodrell D, Connolly K, et al. Phase I trial of AEG35156 administered as a 7-day and 3-day continuous intravenous infusion in patients with advanced refractory cancer. J Clin Oncol 2009;27(10):1660-6
51. Jolivet J, Dean E, Ward TH, et al. A Phase I trial of AEG35156. XIAP antisense) administered as a 2-hour intravenous infusions in patients with advanced tumors. J Clin Oncol 2008(Suppl):abstract 3541
52. Yates JWT, Arundel PH. On the volume of distribution at steady state and its relationship with two-compartmental models. J Pharm Sci 2008;97(1):111-22
53. Geary RS, Yu RZ, Watanabe T, et al. Pharmacokinetics of a tumor necrosis factor-alpha phosphorothioate 2¢-O-(2-methoxyethyl) modified antisense oligonucleotide: comparison across species. Drug Metab Dispos 2003;31(11):1419-28 (Pubitemid 37310332)
54. Levin AA, Yu RZ, Geary RS. Basic principles of the pharmacokinetics of antisense oligonucleotide drugs. In: Crooke ST, editor. Antisense drug technology, principles, strategies and applications. Taylor & Francis Group; Boca Raton, FL: 2007. p. 183-215
55. Watanabe TA, Geary RS, Levin AA. Plasma protein binding of an antisense oligonucleotide targeting human ICAM-1 (ISIS 2302). Oligonucleotides 2006;16(2):169-80
56. Lorenz P, Misteli T, Baker BF, et al. Nucleocytoplasmic shuttling: a novel in vivo property of antisense phosphorothioate oligodeoxynucleotides. Nucleic Acids Res 2000;28(2):582-92
57. Yu RZ, Geary RS, Flaim JD, et al. Lack of pharmacokinetic interaction of mipomersen sodium (ISIS 301012), a 2¢-O-methoxyethyl modified antisense oligonucleotide targeting apolipoprotein b-100 messenger RNA, with simvastatin and ezetimibe. Clin Pharmacokinet 2009;48(1):39-50
58. Baek MS, Yu RZ, Gaus H, et al. In vitro metabolic stabilities and metabolism of 2¢-O-(methoxyethyl) partially modified phosphorothioate antisense oligonucleotides in preincubated rat or human whole liver homogenates. Oligonucleotides 2010;20(6):309-16
59. Crooke RM, Graham MJ, Martin MJ, et al. Metabolism of antisense oligonucleotides in rat liver homogenates. J Pharmacol Exp Ther 2000;292(1):140-9 (Pubitemid 30026364)
60. Wojcik M, Cieslak M, Stec WJ, et al. Nucleotide pyrophosphatase/ phosphodiesterase 1 is responsible for degradation of antisense phosphorothioate oligonucleotides. Oligonucleotides 2007;17(1):134-45 (Pubitemid 46651435)
61. Buckley D, Kazmi F, RYerino P, et al. Inhibition of cytochrome P450. CYP) enzymes, CYP1A2 and CYP2C8, by oligonucleotides in human liver microsomes (HLM): a system dependent outcome. Drug Metab Rev 2009:41 (Suppl 3):abstract 193
62. International Transporter Consortium. Giacomini KM, Huang SM, et al. Membrane transporters in drug development. Nat Rev Drug Discov 2010;9(3):215-36
63. Laskin JJ, Nicholas G, Lee C, et al. Phase I/II trial of custirsen (OGX-011) an inhibitor of clusterin, in combination with a gemcitabine and platinum regimen in patients with previously untreated advanced non-small cell lung cancer. J Thorac Oncol 2012;7(3):579-86
64. Adjei AA, Dy GK, Erlichman C, et al. A phase I trial of ISIS 2503, an antisense inhibitor of H-ras, in combination with gemcitabine in patients with advanced cancer. Clin Cancer Res 2003;9(1):115-23 (Pubitemid 36109723)
65. Mani S, Rudin CM, Kunkel K, et al. Phase I clinical and pharmacokinetic study of protein kinase C-alpha antisense oligonucleotide ISIS 3521 administered in combination with 5-fluorouracil and leucovorin in patients with advanced cancer. Clin Cancer Res 2002;8(4):1042-8 (Pubitemid 35177353)
66. Moore J, Seiter K, Kolitz J, et al. A Phase II study of Bcl-2 antisense (oblimersen sodium) combined with gemtuzumab ozogamicin in older patients with acute myeloid leukemia in first relapse. Leuk Res 2006;30(7):777-83 (Pubitemid 43816693)
67. Motl SE. LY900003: a novel compound for the treatment of non-small cell lung cancer. Cancer Ther 2003;1:237-44
68. Villalona-Calero MA, Ritch P, Figueroa JA, et al. A phase I/II study of LY900003, an Antisense inhibitor of protein kinase C-alpha, in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer. Clin Cancer Res 2004;10(18 Pt 1):6086-93 (Pubitemid 39287513)
69. Tillman LG, Geary RS, Hardee GE. Oral delivery of antisense oligonucleotides in man. J Pharm Sci 2008;971):225-36